1
3
4
News & Events
InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO
September 27, 2023
Joshua Stahl has been appointed as Chief Executive Officer to guide the company's next phase of commercial growth. Read more
FDA Updates for the Week of July 17, 2023
July 22, 2023
The FDA has cleared several new products this week. Read more
Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP®
June 27, 2023
Cefepime/enmetazobactam is a 4th generation antibiotic for the treatment of complicated urinary tract infections. Read more
6
7
News & Events
InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO
September 27, 2023
Joshua Stahl has been appointed as Chief Executive Officer to guide the company's next phase of commercial growth. Read more
FDA Updates for the Week of July 17, 2023
July 22, 2023
The FDA has cleared several new products this week. Read more
Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP®
June 27, 2023
Cefepime/enmetazobactam is a 4th generation antibiotic for the treatment of complicated urinary tract infections. Read more
14
Championing
collaborations
that improve health
and the quality of life
for everyone.

#JoinForces
#LifeSciencesInTheFuture
21
25
29
35
37
News & Events
InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO
September 27, 2023
Joshua Stahl has been appointed as Chief Executive Officer to guide the company's next phase of commercial growth. Read more
FDA Updates for the Week of July 17, 2023
July 22, 2023
The FDA has cleared several new products this week. Read more
Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP®
June 27, 2023
Cefepime/enmetazobactam is a 4th generation antibiotic for the treatment of complicated urinary tract infections. Read more
39
41